BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 6, 2006
View Archived Issues
Anti-AML activity of the shepherdin peptide
Read More
Novel anthrax therapy targeting host receptors
Read More
ONO-2506 active in experimental autoimmune encephalomyelitis models
Read More
Data on Sativex in multiple sclerosis patients accumulates
Read More
ZK-304709 inhibits osteolysis and tumor burden in a murine model of breast cancer bone metastasis
Read More
Preclinical efficacy of sclerostin MAbs in increasing BMD and strength in OVX rats and monkeys
Read More
ACE-011, a novel activin antagonist, improves BMD and bone architecture in OVX mice
Read More
Xanthus licenses U.S. rights to oral fludarabine
Read More
U.K. consortium to develop next-generation treatment for coronary artery disease
Read More
CrystalGenomics presents a new candidate for isoniazid-resistant strains of M. tuberculosis
Read More
UCB and Jazz expand Xyrem license agreement to include fibromyalgia syndrome
Read More
Spotlight on AR-709, Arpida's antimicrobial clinical candidate
Read More
Zevalin studied in new phase III trial for diffuse large-B-cell lymphoma
Read More
Additional data requested by MHRA for Abasol approval
Read More
Celltran and Xcellentis complete merger
Read More
Canadian clearance for second phase III study of ISA-247 in psoriasis
Read More
TorreyPines Therapeutics completes merger with Axonyx
Read More
Collegium's IND accepted for combination allergic rhinitis product
Read More
Phase II study of MTR-106 for acute migraine without aura on schedule
Read More
Anticancer compound AVE-1642 enters clinical testing
Read More
Treatment begins in second phase III trial of cangrelor in PCI
Read More
AVI-4065 results in HCV lead to protocol modification
Read More
SRT-501 safe and well tolerated in phase I studies
Read More
R&D highlights from the UBS Global Life Sciences Conference in New York: Neuromed Pharmaceuticals
Read More
Yaz approved for premenstrual dysphoric disorder
Read More
Fast track designations for talactoferrin alfa in NSCLC and diabetic foot ulcers
Read More
European approval for Suboxone for treatment of opioid dependence
Read More
FDA approves FluLaval
Read More
New Vytorin label approved
Read More
Tokyo University of Science patent discloses novel agents for preventing transplant rejection
Read More
Development of obestatin peptide derivatives reported by Leland Stanford Junior University
Read More
Recent patents impart new agents for atherosclerosis, hypertension, etc.
Read More
Inhibition of LPS synthesis by WaaC inhibitors shows promise as novel antibacterial strategy
Read More
